Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Gow, Y-L. Chang, Y-C Hsu, Meng-Feng Tsai, C.-T. Wu, C-J. Yu, C-H Yang, Y-C Lee, P. Yang, J. Shih (2009)
Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 20 4
U. Gatzemeier, A. Płużańska, A. Szczesna, E. Kaukel, J. Roubec, U. Brennscheidt, F. Rosa, B. Mueller, J. Pawel (2004)
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 22
A. Davies, P. Hesketh, L. Beckett, D. Lau, P. Mack, P. Lara, J. Jernigan, J. Lapointe, D. Gandara (2007)
Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonismJournal of Clinical Oncology, 25
Sreenath Sharma, D. Bell, J. Settleman, D. Haber (2007)
Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 7
G. Badalian, T. Barbai, E. Raso, Katalin Derecskei, M. Szendrői, J. Tímár (2008)
Phenotype of bone metastases of nonsmall cell lung cancer: Epidermal growth factor receptor expression and KRAS mutational statusPathology & Oncology Research, 13
M. Morelli, T. Cascone, T. Troiani, T. Troiani, F. Vita, M. Orditura, G. Laus, S. Eckhardt, S. Pepe, G. Tortora, F. Ciardiello (2005)
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology, 16 Suppl 4
E. Lindhagen, A. Eriksson, M. Wickström, K. Danielsson, B. Grundmark, R. Henriksson, P. Nygren, A. Åleskog, R. Larsson, M. Höglund (2008)
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemiaEuropean Journal of Haematology, 81
D. Eberhard, B. Johnson, L. Amler, A. Goddard, Sherry Heldens, R. Herbst, William Ince, P. Jänne, T. Januario, David Johnson, P. Klein, V. Miller, M. Ostland, D. Ramies, Dragan Sebisanovic, Jeremy Stinson, Yu Zhang, S. Seshagiri, K. Hillan (2005)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
R. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B. Johnson, A. Sandler, M. Kris, H. Tran, P. Klein, Xin Li, D. Ramies, David Johnson, V. Miller (2005)
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
Tomoaki Tanaka, M. Matsuoka, A. Sutani, A. Gemma, M. Maemondo, A. Inoue, S. Okinaga, M. Nagashima, S. Oizumi, K. Uematsu, Y. Nagai, Gaku Moriyama, H. Miyazawa, K. Ikebuchi, S. Morita, K. Kobayashi, K. Hagiwara (2010)
Frequency of and variables associated with the EGFR mutation and its subtypesInternational Journal of Cancer, 126
C. Schneider, D. Heigener, K. Schott-von-Römer, S. Gütz, E. Laack, W. Digel, W. Guschall, A. Franke, H. Bodenstein, C. Schmidtgen, M. Reck (2008)
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST StudyJournal of Thoracic Oncology, 3
L. Tanoue (2007)
Erlotinib in Previously Treated Non-Small-Cell Lung CancerYearbook of Pulmonary Disease, 2007
T. Chou, P. Talalay (1984)
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.Advances in enzyme regulation, 22
C. Mahaffey, A. Davies, P. Lara, B. Pryde, W. Holland, P. Mack, P. Gumerlock, D. Gandara (2007)
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.Clinical lung cancer, 8 9
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
D. Solit, Y. She, Jose Lobo, M. Kris, H. Scher, N. Rosen, F. Sirotnak (2005)
Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to PaclitaxelClinical Cancer Research, 11
O. Weigert, A. Pastore, M. Rieken, N. Lang, W. Hiddemann, M. Dreyling (2007)
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphomaLeukemia, 21
N. Hanna, F. Shepherd, F. Fossella, J. Pereira, F. Marinis, J. Pawel, U. Gatzemeier, T. Tsao, M. Pless, T. Muller, H. Lim, C. Desch, K. Szondy, R. Gervais, Shaharyar, C. Manegold, S. Paul, P. Paoletti, L. Einhorn, P. Bunn (2004)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 9
Masayuki Shiseki, Takashi Kohno, Ryo Nishikawa, Y. Sameshima, Hideaki Mizoguchi, Jun Yokota (1994)
Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma.Cancer research, 54 21
M. Mounawar, A. Mukeria, Florence Calvez, R. Hung, H. Renard, A. Cortot, Claire Bollart, D. Zaridze, P. Brennan, P. Boffetta, E. Brambilla, P. Hainaut (2007)
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.Cancer research, 67 12
J. Dancey, E. Sausville (2003)
Issues and progress with protein kinase inhibitors for cancer treatmentNature Reviews Drug Discovery, 2
Tianhong Li, Y. Ling, I. Goldman, R. Perez-soler (2007)
Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer CellsClinical Cancer Research, 13
A. Davies, Primo Jr, P. Mack, D. Gandara (2003)
Docetaxel in non-small cell lung cancer: a reviewExpert Opinion on Pharmacotherapy, 4
Erlotinib is used as a standard treatment for recurrent advanced non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) mutations in NSCLC have been shown to be a predictive factor of erlotinib, although the relationship between K-ras oncogene (KRAS) mutations and erlotinib resistance is controversial. Recently, in vitro sequence-dependent interactions of erlotinib and docetaxel have been studied on as a novel therapeutic approach against NSCLC. The purpose of the present study was to determine the optimum novel regimen of erlotinib and docetaxel against NSCLC cells which have EGFR mutation (HCC827 cells), KRAS mutation (A549 cells) or both wild-type (NCI-H292 cells). First, we analyzed the effects of in vitro combination for cell proliferation-inhibition using a combination index. In all cell lines, docetaxel followed by erlotinib treatment showed nearly additive effects. On the other hand, erlotinib followed by docetaxel treatment showed remarkable antagonistic interactions. Second, we examined the effect of combinations on the in vitro apoptosis induction. Erlotinib followed by docetaxel treatment reduced apoptosis induction compared with docetaxel alone; in contrast, docetaxel followed by erlotinib treatment had no inhibitory effects on docetaxel-induced apoptosis in any of the cell lines. Finally, an in vivo tumor growth inhibition test was performed using xenograft models. Docetaxel followed by erlotinib administration resulted in significant tumor growth inhibition compared with erlotinib or docetaxel monotherapy in all models. In conclusion, we demonstrated that docetaxel followed by erlotinib therapy was a potentially optimum regimen against NSCLC regardless of the mutation status of EGFR and KRAS.
Oncology Reports – Spandidos Publications
Published: Nov 1, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.